"Winners keep winning." Whatever one thinks of this adage, it certainly seems to apply to Eli Lilly (NYSE: LLY). The pharmaceutical giant has been on a tear, racking up important clinical and regulatory victories in the past few years. The result: Eli Lilly has soundly crushed the market in the past five years, and the company is at it again. A recent regulatory win further improved Eli Lilly's prospects. Let's take a closer look.

Over the past two decades, few therapeutic areas in the pharmaceutical industry have been harder to crack than Alzheimer's disease (AD). Though drugmakers have poured millions into developing novel AD therapies, their efforts have mostly resulted in failures. Even Aduhelm, an AD medicine that became the first to earn the green light in the U.S. in 18 years in 2021, ended up being a monumental flop because physicians refused to prescribe it due to poor efficacy data.

This background helps highlight how important Eli Lilly's most recent brand-new approval is. The company earned the thumbs-up from the U.S. Food and Drug Administration (FDA) for Kisunla, now indicated to treat early symptomatic AD. Kisunla didn't have an easy path to approval. But unlike with Aduhelm, a panel of experts convened to discuss the new AD medicine unanimously voted in favor of approval.

Continue reading

Source Fool.com